Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
| Autor: | Satoshi Shinozaki1,2 shinozaki-s@aqua.ocn.ne.jp, Toshiyuki Tahara3, Kouichi Miura2, Alan Kawarai Lefor4, Hironori Yamamoto2 |
|---|---|
| Zdroj: | Clinical & Experimental Hepatology. 2022, Vol. 8 Issue 4, p278-283. 6p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|